Admin

CancerLife, a Digital Health Company with the Validation Institute, Announced Results of its Phase 3 Trial That Raised EQ-5 Quality of Life (QOL) Scores by 14.3%

Philadelphia, PA (June 2, 2022) – CancerLife, a digital therapeutics company and the Validation Institute, announced the results of its two-arm, fully randomized Phase 3 clinical trial today, which concluded that the consumer cancer app was proven to raise the quality of life in cancer patients by 14.3%. This marks the first cancer social support platform that does not require remote patient monitoring or is needed to be implemented inside a cancer center to raise QoL. CancerLife is now available for download in the app stores, and now any patient can improve their QoL regardless of where they live.

CancerLife’s goal is to improve the experience for any cancer patient regardless of where they receive care. By using social behavioral therapy and novel data collection reporting, CancerLife helps patients change how they think and experience their cancer diagnosis while identifying and lowering the symptom burden by 66%. This improves their quality of life, regardless of the care location. “We believe doctors will recommend CancerLife to their patients with these clinical trial results as they are under constant pressure to improve the patient experience.” Doctors will benefit because CancerLife raises QoL without any workflow or investment in time by their cancer care staff.

“What sets us apart from any other digital therapeutics company is that we are the first company that combines the mental and physical impact of cancer treatment inside one platform,” said Charles Coltman, Founder and CEO of CancerLife. “14.3% may not seem a lot, but it translates to feeling better one extra day a week, and for cancer patients, that means spending more time with family and friends”.

Validation Institute, an independent third-party organization, has validated the study results by having its epidemiology team review the study’s design, data sources, and analysis approach. Validation Institute works with some of the most highly valued digital health companies, such as Hinge Health and Virta Health.

“Two armed, randomized trials are rarely attempted in the digital health industry and CancerLife has raised the bar with these results,” stated Benny DiCecca, CEO of Validation Institute. “The analysis clearly demonstrated the impact that the CancerLife solution can have in patients’ lives.”.

CancerLife can also provide its platform to other digital health, advocacy groups and pharmaceutical companies in both a reseller model or “white label” solution, including other diseases with high symptom and QoL burden. “We are ready to partner with other companies who want to leverage our technology within the cancer care and specialty disease space.” said Mr Coltman.

About CancerLife:
CancerLife was founded by Charles Coltman, who lost his best friend in 2013 to pancreatic cancer. CancerLife helps patients change how they think and experience their cancer diagnosis, whilst identifying and lowering the symptom burden. This has a dramatic impact on quality of life, regardless of the care location. CancerLife is now live in the app stores. https://cancerlife.com/install

About Validation Institute:
Validation Institute is an independent, objective, 3rd party organization on a mission to improve the quality and cost of healthcare. Based in Woburn, MA, the organization is made up of a network of health benefits purchasers, health benefits advisors, and healthcare solution providers focused on delivering better health value and stronger outcomes than conventional healthcare. www.validationinstitute.com

Psychedelic Therapy and Cancer Care ? Where do we stand?

Hi friends, Charlie here. I want to talk about an exciting topic that is really taking over both the digital health space, health care, as well as wall street. And that’s the exciting developments in the use of psychedelics for mental health treatment? I think in the last 90 days we seen three companies go public and they’re almost viewed while they are viewed as you know therapeutic biotech companies. And the revolution in the science has actually been around for awhile. I guess you call it a revolution that it’s more a revolution of adoption and acceptance than it is about some type of breakthrough. Just a little history of the psychedelic movement where it’s really it’s really starts. I think with Johns Hopkins has a school for psychedelic studies and I have been working for almost 10 years now on studies that associate with post-traumatic stress disorder using psychedelics and guided therapies.

So keep in mind, this is at this stage, it’s not, we’re not talking about, you know, just handing somebody a tab of acid and saying, good luck with that, all that. This is using certain dosages, low dosages that are then paired with therapy, so guided meditation and or guided therapy. So, you know, the psychedelics and this we’re talking about psilocybin MDMA, which is ecstasy. You know there’s a few other ones, but essentially, you know, the science is amazing. I mean, it’s just basically, if you combine, you know, getting a therapist to key in, on some trauma I E and with vets and, and you know, post-traumatic stress, the psychedelics allow the brain to kind of gain a perspective and there’s almost a rewiring of the neurons with that trauma. And it is just a kind of a doorway. It’s a re rewiring process that is dramatic.

It is a literally like rewiring a computer with natural compounds, so that that’s, what’s incredible. And Johns Hopkins, they did a five-year study with posttraumatic stress disorder. We’re talking fives, I’m sorry, three sessions you know, guided, guided trip sessions with therapy therapists. And after five years, something like 75% of the participants had no indications of post-traumatic stress had no issues with depression. It was just, it’s unbelievable. So that’s kind of started a whole revolution and, you know, now these psychedelic compounds are being experimented with whether they’re actually making artificial compounds at campus pathways and law in England, or, you know, just experimenting with magic mushrooms you know, with therapy. So where does this all sit with cancer patients and my company, and what’s our vision, what’s our kind of stance on this whole thing. And I think I will say it right now.

I think we, as a company and as you know, patients, you know, who are dealing with end of life, you know, we should be at the forefront of both, either partnering with companies who are trying to develop these therapies from a clinical trial perspective you know, or having our own sort of services associated with end of life, palliative care hospice. I mean, I think going forward, I’m talking about, you know, 12 to 24 months from now, you know, our movement is going to be into end of life care. And I think that what needs to be done and how I see it evolving is, is it’s, it’s a preparation, it’s a process, it’s a preparation. And these types of therapies have shown to load low lowering anxiety, give great perspective. And I can’t, you know, I believe it’s going to be big.

I think it’s going to be a standard of care for hospice treatment, probably in the next, you know, three to five years. You know, I want to tell those two stories associated with cancer patients and psychedelics one is a woman who had pancreatic cancer diagnosed pancreatic cancer twice. I mean, and still living today. She was part of the joy of the Johns Hopkins study. And I, she and I spoke at length about her experience. And she said that the experience completely wired her rewired, her brain, that she felt less fear about death than she ever had. She told me just jokingly. She said, honestly, every day I wake up and I look myself in the mirror and say, one day you’re going to die, but not today. And for someone that has faced such a horrible diagnosis, I mean, that’s, that’s magical to me.

Number two is even more personal story about a friend of mine that I was introduced to. I want to say seven years ago his name was Dan and Dan had childhood brain cancer around. I want to say when he was 10 to 12 years old. And through the treatments, you know, two years of treatments, two years of surgeries it left him really kind of, you know, sort of limited in, in his intellectual capacity. So to speak and years later, almost 20 years later, he got rediagnosed with the same cancer. The cancer had come back and that’s what I was introduced to him. And we spent a lot of time together. It was very clear to me that a lot of his friends pull back after this diagnosis kind of like, you know, it was almost like they had decided he was already gonna die and they didn’t want to deal.

So I spent a lot of time with him. In fact, I used to go down and hang out with him every Wednesday when I was headed down to the city for therapy, I used to sit with him for four to five PM almost every Wednesday just to talk. I mean, just, he needed a friend and we spent a lot of time. And one of the saddest moments for him was when he told me I’m really depressed. And I said, why? He goes, because they told me the tumor is shrinking. And I said, oh my God, Dan, like, what do you mean? He’s like, I’m just done. I feel like I have no life. I feel like I’m lonely. I feel like I don’t want to live like this anymore. And, you know, he was really in a, in a, you know, a dark place.

His parents were well aware of his emotional status. And, you know, I tried to really respect him as a person and wishes and, and just tried to listen and be supportive a few weeks later. I actually took him down to my mother’s beach house for the weekend. And, and we did a mushroom trip together. I had, I’d known that, that this, you know, had shown evidence of improving, you know, mental outlook and, you know, he was all for it. And I can tell you, you know, after that experience, he, his whole mood changed. I mean, it was dramatic. His parents say, Charlie, like, you know, what, what did you do with a weekend? And I’m like, well, we just talked a lot. That’s all I could kind of disclose. But it was at that moment where I realized there was something, there was something to this, and that’s actually what started me on my education of, of silicide bean and the work with Dr.

Paul Stamets out in his facility has his research Institute out in the Northwest. So I, you know, unfortunately about six months after that experience, Dan committed suicide he had fallen back in and, you know, everyone had done everything we could to, to sort of try to convince them otherwise, but that was his choice. And I’m certainly not condoning suicide as a method for folks. But I can understand. I mean, all I can say is I can understand when we I’ve said this before in my previous post about symptom management, quality of life and depression, it’s like when you have no quality of life and you have no function, you lose meaning and you fall into depression and that can lead to a place of, of frankly giving up. So the bottom line from my perspective and my company’s perspective is we are, you know, 1000% supportive of the use of psychedelics for end of life cancer died, you know, treatment.

I, you know, I want to lead in this area and I’m, you know, I’ll say to any, any psychedelic research companies that are involved, who want to get in the cancer space, we are open for business to try to partner up with you guys to, to both find patients and run studies. And I’ve got some amazing contacts in the space. And it’s something that I can see, like I said, in five years, where part of the service offering is, you know, in, in some type of hospice end of life care would be the use of guided psychedelic therapy. So that’s my take on it. Wishing all the best and take care.

100 Daily Active Users!! Why is this so exciting?

Well we finally did it we hit 100 daily active users!! That might not seem like a lot for many people but when you consider that cancer patients are roughly 2% of the population this is significant in that the typical target point for Silicon Valley to invest in consumer apps is 10,000 daily active users, so we’re on our way up to 1000 daily active users which is going to be our major milestone we hope to hit in September.

 For more information around daily active users and Silicon Valley please see the posts and interview with Jeremy Lou from lightspeed ventures.

https://www.vox.com/2017/11/18/16673982/app-growth-investors-jeremy-liew-snapchat

CancerLife 2020 Study Results Overview

Marlon Saria, PhD

John Wayne Cancer Institute

Charles Coltman

CEO Founder of CancerLife

CancerLife announces results of pilot study of its digital therapeutic which showed a 25% improvement of QoL metrics and reduction of symptom burden by 70% with its most active users. Expands study to 1,000 and adds randomization to its virtual clinical trial.

Introduction

There is no doubt that patients diagnosed with cancer live longer due to advances in immunotherapy and more early detection methods. Cancer and its treatment, however, produce multiple symptoms that significantly distress patients and impair function. Such common symptoms and often go undetected can include fatigue, depressive symptoms, cancer-related pain, and other bodily changes. These symptoms can delay or lead to premature treatment termination, depression, poor quality of life outcomes, and lead to hospitalizations and emergency room visits to manage these symptoms.

Patient reporting of symptoms or patient-reported outcomes (PROs) has been a suggested approach to improve both the control of symptoms and improved quality of Life metrics and even a dramatic improvement in overall survival* (Basch 2017). There are several ways to collect these symptoms (PROs), but none are required as part of the standard of care. Patient portals have attempted to use their electronic communication to capture this data when the patient initiates an engagement. Still, evidence has shown the patients rarely engage on these systems frequently enough to capture enough data to build a comprehensive picture of the patient’s health status. Health systems and cancer centers have responded by piloting remote patient monitoring studies that have initiated engagement from the provider to the patient using text messages and or email communications. ( Basch 2017) Remote patient monitoring systems offer significant benefits and have shown to improve outcomes and lower hospitalizations.

However, remote patient monitoring presents significant workflow disruption to a busy Cancer Center that responds to patient’s needs when needed. Community oncology practices also are limited by the number of resources available to answer to these remote patient monitoring systems and therefore are not practical in real-world community ecology settings.

Our study’s purpose was to show that empowering patients with a digital health platform called Cancerlife, will lead to more effective, longitudinal data collection, thereby improving quality of life metrics. Our platform also solves the particular problem of patient engagement by allowing users to share their health status with other patients, which provides meaningful social support during treatment. It’s this specific social interaction that generates significant emotional reward while at the same time enabling the level of data collection of patient-reported outcomes needed to impact the quality of life outcomes and metrics.

We hypothesized that by empowering patients to collect their data and providing print- out reports that could be shared manually with the patient’s care team, more effective communication and management of symptoms would lead to a higher quality of life scores.

Fundamentally, we asked a simple but essential question: Do patients have the ability to collect their own symptoms and share this data with their care team using a novel digital health solution?

Finally, this study’s key focus was to assess the engagement metrics within the digital health solution Cancerlife focused on the number of times a week, patients shared their health status without being prompted. Also, the number of times patients engaged with other posts, comments and likes similar to other social networks like Facebook, and we also looked for correlations between the number of times patients engaged on the platform and their quality of life scores.

Our goal was to show meaningful improvement in outcomes metrics by using and engaging the CancerLife digital health solution and sharing the data collected with the care team.

We hypothesized that using digital data capture and communication platform can improve quality of life and enhance physician–patient interaction in patients with cancer and their caregivers. Our study showed that CancerLife optimized self-monitoring and reporting of symptoms and showed promise in reducing symptoms in highly engaged participants.

Our study showed that empowering patients by using a digital information and communication platform that could be logged into at any time (24/7) would create similar data collection observations that could present to the care team at the time of consultation without the need for clinical intervention. 78 Patients in our study logged onto CancerLife and posted and shared their health status on average 2.2 times per week for up to 20 weeks. This data highlights the benefits of the digital communication platform showing a reduction in symptom burden in patients diagnosed with cancer. Patient-reported outcomes (PROs) collected longitudinally by the patients are equally effective at lowering symptom burden and improving the patient’s quality of life. For those who were the most active (top 25% of users) on the Cancerlife platform, saw an average improvement in QoL metrics (FACT-G survey) was 24.7 % while reducing their symptom burden by 79%.

Conclusion

In conclusion, these results show the importance of digital communication and improving quality of life and symptom burden using the CancerLife platform. One of the key goals of this study was to prove that cancer care outcomes can be achieved when the patients can collect better data themselves and present their data to the care team at the time of consultation.

Although Remote Patient Monitoring systems have clear benefits, the resource constraints on the care team’s daily workflow make implementing these RPM systems a burden to many health systems or independent offices, especially in the community oncology setting. Our theory has been that the issues with symptom management within cancer care is partly a data collection and sharing problem. Empowering patients with a platform to easily collect and report this data back to care teams without the workflow burden of asynchronous messaging would achieve meaningful outcomes. Ultimately the ideal state in any high burden disease is real-time communication with the patient’s care team and doctor. But in practice, this is highly unrealistic. Even in the most patient-centric practices the cost and burden are incredibly high. CancerLife is designed to empower patients to share this burden in an easy-to-use app that creates reports that are shared manually at the time of face-to-face or online consultation. We believe Cancerlife achieves meaningful outcomes with limited workflow and operations burden on practices and ultimately will be preferred by cancer practices with limited time and resources.

After the study conclusion and analysis, we are expanding our current study protocol and changing the QoL measure to the EQ-5 European scale, which will be better suited to a digital solution like Cancerlife. Furthermore, we add a randomization component to our virtual study and expand to over 1000 participants. We believe that after the results of this randomized control trial, we will be the first and only direct to consumer app that is clinically validated to improve QoL through better patient driven symptom management and engagement.

Virtual Reality used in Cancer Care …coming soon to a headset near you!

Charlie Coleman here, CEO and founder of Cancerlife today’s video blog, is about some exciting research that just came out at temple from temple university and Dr. Antonio Giordano and D, who with his Italian team created a virtual reality experience that lowered anxiety and stress in patients undergoing chemotherapy.

This is important in two ways; one, it’s a vindication of the power of virtual reality as a method to improve mental health outcomes specific to a disease. We know that getting chemotherapy in an infusion center is stressful for patients. Just the whole experience of going to the doctor with the reality of, Oh my gosh, you know, here I am, again, sitting in the chair. Cancer centers have tried for years to make the experience better. And yet, using this virtual reality headset and experience, they measured, you know, stress levels and anxiety measures and saw incredible outcomes.

So I think that’s exciting just from a VR perspective on, on this type of technology. The second thing is specific to cancer. You know, we know that cancer outcomes have a direct impact on stress levels. Dr. Lutkendorf out of the University of Iowa showed that the more social support or, or more loneliness that patients have the worse, outcomes. Because then the stress level induces tumor growth. \

Whatever we can do to lower stress for patients is a good thing for cancer Carol across the board. The second thing is that many patients are experiencing stress levels, not just in the infusion chair but when at home. Right? So, you know, they typically, and it, a lot of the times, it’s two in the morning in our experience at castle life.

A lot of the times when patients express their extreme level of, of anxiety and worry, you know, it’s because it’s two in the morning and it’s the night before they’re getting there, you know, major scan or they’re getting results of a blood test, or, you know, a genetic marker. These are all critical decision points for patients. And they’re experiencing this excitement, anxiety, and stress when no one else is around right there. They’ve got no options to engage with, you know, a social worker or some type of coach. You know, although our patients can interact with each other late, late in the, in the middle of the night. What’s interesting with this VR technology, this is something that I assume over time will be scalable to the home where patients can feel that anxiety and then, you know, put on the headset and go through some breathing exercises, some mindfulness and instead of just a visual recording, they’ve got a full virtual reality experience. That’s going to calm them down.

So I just think it’s really exciting information and, and research and looking forward to talking to Dr. G about potentially partnering with his organization and scaling this technology. So anyway take care and best of all to my wonderful members of Cancerlife.

Are cancer non-profits dead? What does their future look like in the post covid era?

The following is transcription of this video.

Hi, Charlie Coleman here, CEO and founder of CancerLife today’s blog post  on some news that came out from Susan B Komen the famous breast cancer non-profit in which they announced that the Philadelphia Pittsburgh operation is going to be closed. This is big news, Susan B Komen obviously everyone knows for many years has raised billions and billions dollars, uh, to medical research. Um, you know, one of the first organizations began their fundraising around five Ks and walk for breast cancer. That was their really their primary source. And then obviously, yeah, adding the famous pink ribbon to every consumer brand out there, um, you know, going through directly to corporations to support breast cancer research, which was quite innovative. I want to give them kudos those four, you know, at least the money that they were raising, um, was coming from across, you know, multiple avenues and yeah, and spectrum of providers.

I mean, there’ll be a lot of folks that talk about the fact that only 30% or less of their money raised each year goes to actual research. That gives you the sense of how big their fundraising operation is but I mean to say that, you know, that, that they’re in yeah, haven’t contributed to, um, the breast cancer causes a little, I think, um, disingenuous, but one of the things that I’m wanting to talk about with this blog post is the question that I pose, which is our cancer nonprofits dead.

I think over the last three years, CancerLife has reached out to every cancer non-profit of significance. It’s both the big ones and we all know who they are. I mean, I’ve been down to Atlanta at the American cancer society about five years ago, trying to do a partnership, um, Susan B Komen living beyond breast cancer, um, you know, cancer support community, which was the Gilda’s club.

 I’ve spoken all of them and I even went to other smaller ones and the thing that I tried to explain to them was that I felt that their business model was changing in terms of fundraising. I don’t believe in even this is before the pandemic that people have the time to do 5k events. I mean, live strong is another prime example of an organization, you know, um, Lance Armstrong, bike races, um, and that whole community. And when, when Lance left, you know, I think when after Lance left live strong, I think in their major, you know, bike race event, I think it was in Austin, maybe it was in Dallas. Um, I think they lost like $1.6 million on just on that Ben alone. So, you know, the reality is, is, is I felt like these cancer nonprofits days were really numbered that ultimately they had to embrace a new business model.

And that business model is data and research. Um, you know, it’s shocking to all the nonprofits that I’ve spoken to over the years. There’s how lack of, of community that they’ve really created. I mean, you know, a lot of them don’t even are connected to patients they’re connected to the patient’s families. Maybe they, they, you know, they get these donations after the, the person has passed on, you know, their loved one has passed on. So they donate in their loved one’s honor, but they really never really engaged and built a decent community. I mean, some of them have newsletters, um, but you know, they rarely do. They update the data in terms of what is there, when we try that, you know, for example, when we tried to engage one of the major breast cancer nonprofits, we asked them what their open rate is.

The open rate would be a newsletter email, like what percentage of people were opening your emails and they couldn’t even answer it. They don’t even track the data. So they send out these newsletters. And, you know, I guess what I’m saying, you know, to folks out there is I believe that, you know, the traditional methods of cancer nonprofits, uh, fundraising is by going by the way, the dinosaur, and if you’re an existing cancer non-profit, and you’re not thinking about research data and becoming a data company, you’re really going to go by way of Susan B Komen, as I’ve tried to tell you all before, you know, the cancer platform is designed to collect patient reported outcomes, data, which doesn’t exist, which is the hottest, most important data set that pharmaceutic companies are dying to understand the patient experience. So for cancer nonprofits, you know, there’s a few out of out there.

Uh, I can think of LUNGevity and lung cancer because immunotherapies and Keytruda is so critical and there’s so much money around. And that, um, longevity is one there’s, there’s a couple more that are really pushing the envelope with research. Um, the Multiple Myleoma Foundation is probably the premier cancer nonprofit in the space today. And they’ve been working in genetic cancer data for like five years now when it comes to research. But I’m telling you all you, non-profits out there. If you’re not thinking about data research specific to patients, you’re going to be closing offices. So for those patients who think about, you know, these nonprofits and what it all means, um, you know, it’s a new day and, um, the best way that you can contribute money is great. We know that there are a million places to take it.

If you are a Cancer Nonprofit and need a resource here is a link to Harvard Precision Medicine Accelerator which provides a guide to migrate to a data-driven research company, with support from Multiple Myeloma Research Foundation which has led this data revolution for years! Click here to download the tools and guide. https://www.hbs.edu/kraft-accelerator/use-the-tools.html

What is CancerLife’s competitive advantage in the digital health market?

The following is a transcription of this video post.

So what the question is, why is clinical validation so important to CancerLife and its strategy going forward? Well, I think, I think this is something fundamental and one of the things as I learned or realized, I would say back in early 2016, as I saw the digital health market sort of maturing, I realized clinical validation is going to be the difference between winners and losers in this space, meaning clinical validation we needed to run and show meaningful, measurable improvement in a IRB funded or IRB supported study in order for us to really make headway both from an perspective of investors, but also more, most importantly, from the perspective of cancer patients, the importance of clinical validation is cannot be, you know, kind of under stressed here because in order for get to get patients like you to even consider CancerLife, there’s gotta be a compelling reason.

You know, it’s not just like a new, you know, a consumer app that you’re willing to give a try to you’re, you’re overwhelmed. You may already be part of a Facebook support group. So you’re getting the emotional support that you need from other patients. Why should you, should you be using CancerLife? If you’ve got something else that you’re already using, or I’m just too tired or I don’t have the emotional energy to even try something new. And I totally understand that. And that’s why I realized in order for me, to convince new patients, to give, CancerLife a try, I needed to show them that there was a meaningful, measurable impact in their quality of life in order to convince them to give it a try. That’s why we spent the last three years in our clinical trial at John Wayne Cancer Institute.

It is a Phase 2 study observational in which we tracked nine 119 patients. We recruited them online and, and brought them into the system. And based on quality of life metrics called the fact G survey. We measured them in a 14 question survey metrics. And based on that study, we showed an average improvement of 25% in quality of life metrics and a reduction in symptom burden by 70% symptom burden, meaning the number of symptoms reported, um, each time dropped by an average of 70%. And we know that symptom burden has a direct impact on the quality of life. It’s this result of this study that we feel like it’s now time to launch the cancel life platform to the rest of the universe if you will. Um, secondly, when it comes to our randomized control trial, which is what would be called a phase three study, just like in pharmaceutical development R and D development, we are going to go through a randomized controlled trial of roughly a hundred patients at a vulnerable population in Trenton, New Jersey at capital health.

Um, so this is the highest level of clinical validation where you hope to start that, uh, January of 2021 and be done by June or July of, uh, 2021. And from that, we believe we’re going to replicate our findings and show at least a 20% improvement of quality of life and really make CancerLife a true digital therapeutic. It will be at this point where CancerLife essentially will achieve, uh, something that no one else has achieved, which is an app that has measurable a measurable app intervention, digital therapeutic that improves Quality of Life.

So that’s why in order to get all stakeholders in cancer care to recommend CancerLife, we felt like it was essential that we go through a fully validated clinical validation process and we’ve already achieved Phase 2 something that we can now share publicly and now it’s that we’re going to be moving towards a phase three randomized trial, which is exciting. We are on the precipice of something really magical. And for those of you who are considering CancerLife, please give us a try. Thank you.

Why doctors treat tumors, not patients and how CancerLife can help change that?

The following is a transcription of this video.

Here’s a question? What is the current state of cancer care today? What is Cancerlife’s role in precision medicine ?

So cancer care today is going through a fundamental shift and revolution in care. Immunotherapies have changed the game. We call this precision medicine and it’s because in the past chemotherapy drugs, we’re targeting the kind of the entire system, right in a lung. You know, you took a drug in the lung cancer and you focus a drug in lung cancer, and then you took a separate drug and did kidney cancer. Well now, based on the precision medicine revolution, DNA sequencing, and it being to identify targeted markers, uh, drugs are now targeting specific genetic markers and the, you know, the, the tumor can mutate and those markers can be revealed. Um, and once doctors are always, that’s why you guys are going through so many tests is they’re always trying to see what markers are in that tumor that they can target with immune-drugs, Keytruda being the number one first to market revolutionary drug, probably number one drug in the world right now for their PD one marker, a target.

But the bottom line is doctors today treat tumors. They don’t treat patients. Now, let me say that again. Doctor treat tumors. They don’t treat patients and that’s okay. That is not, you know, no, some attack on oncologists, not at all, but it’s important for patients to understand that that’s where your doctor’s head is, right? There are focused on that tumor, the focused on those markers and the infinite amount of knowledge that is happening right now that is required by your physician. To be able to treat tumors in this way is exponential. They are truly overwhelmed. Unfortunately, their documentation requirements, um, that they have to do using their electronic medical record is painfully slow and burning out doctors left and right, they’re really, truly, um, overwhelmed when it comes to just the day to day grind of delivering cancer care. And that knowledge requirement is only going to go up.

I think I saw a statistic. That’s saying doctors only spend 12 minutes a month with each patient. Think about that 12 minutes. And I unfortunately think that that number is going to drop by 30% over the next few years. They’re just not going to have the time, but for a patient who’s going through treatment right now and maybe a CancerLife user. Um, you have to understand that you have to help your doctor help you. They’re not mind readers. They don’t know what’s going on in your life. You’re waiting for them to ask to probe deeper, to, to really understand what your values are. And the bottom line is your values change over time, right? I mean, you started when you got diagnosed, your value, every cancer patient has the same value on day one, which is cure me, get me back to my life that I was living.

I was really happy. Um, but you know, you take cancer care over 18 months and you know, the side effects, the symptoms weigh you down, you’re in pain, your fatigue or nauseous, all these things, 18 months later, you’re, you’re just exhausted.

And that’s where CancerLife comes in, which is collecting quality of life, data, sharing your reports with your doctor, you know, and being, being able to communicate your value of what quality of life means to be able to track. Are you able to get through your routine your every day and if you’re not use the CancerLife platform to collect this data, and then, you know, as we show you inside the platform, we were going to be showing you what other cancer patients are experiencing, not just from day to day symptom management perspective, but overall quality of life across specific, um, tumor types and, and treatments so that you can go to your doctor and say, Hey doc, you know, I’m looking at the camera, it’s life, community data.

And it’s telling me that on my same treatment, looking at 150 plus patients, they have 30% higher quality of life. I do like maybe is there another option for me? Can we slow down? Can we course correct? Can we lower the dosage? I mean, there’s a million things that, that your doctor can do, but it’s up to you to bring that data to the table. So to answer that, you know, what is this state of cancer care today and what is, you know, CancerLife, his role in the precision medicine revolution? I think it’s, it’s really finally bringing quality of life to the table so that each patient can be, you know, looked at individually and be able to share that data. So your doctor truly knows what your values are and when you reach that breaking point and really want to, you know, take a step back and just enjoy every moment, um, in your life with family and friends, being able to say to the doctor, Hey, you know, look at this quality of life data, and let’s adjust my treatment plan. That’s what a CancerLife’s role is within the precision medicine revolution. Thanks a lot.